A pilot early phase 1 trial (NCT07261657) represents the first clinical effort to activate persisting transferred rare persisting cells by using IL-15 superagonist N-803.
Daphne P. Edgren, BFA
Advertisement
Articles by Daphne P. Edgren, BFA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Cardiac Assessment With Atrial Fibrillation and Closing Thoughts
2
FDA Receives BLA for Etentamig in Relapsed/Refractory Multiple Myeloma
3
Prior ICI Exposure Linked to Higher Dermatitis Risk With Lirafugratinib in FGFR2-Altered Tumors
4
Cisplatin-Free Pembrolizumab Regimen Misses Primary End Point in SMART-KEY
5